EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Baseline Biomarkers for Three-Year Fibrosis Development on OCT in Treatment-Naïve Neovascular AMD

Malcolm Fayers, Long T. Phan, Eden McDonogh, Kimberly L. Spooner, Andrew A. Chang, Hemal Mehta, James G. Wong

Journal of Personalized Medicine · 2026-10-30 · 16 (11) · 560

DOI: 10.3390/jpm16110560 ↗
AbstractBibliografische Angaben

Abstract

Aims: To explore how baseline biomarkers on optical coherence tomography (OCT) predict fibrotic development in eyes with neovascular age-related macular degeneration (nAMD) commencing intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. Methods: Medical records at a single institution were retrospectively searched to identify eyes starting anti-vascular endothelial growth factor therapy with 36-month follow-up. Baseline OCT images were graded for central subfield thickness (CST) and nAMD lesion features. The development of fibrosis was determined after three years using an OCT-based approach, and multivariable logistic regression was used to identify independent predictors. Results: A total of 201 eyes were included, of mean age 77.3 years. At baseline, median visual acuity (VA) was 67 (IQR 58–77) letters, and mean central subfield thickness (CST) was 398.6 ± 135.3 µm. Mean injections received were 9.8 ± 1.9, 8.1 ± 3.1, and 7.3 ± 3.2 in years 1, 2, and 3, respectively. Fibrosis developed in 53 eyes (26.4%) by three years. Lower baseline VA (OR 0.68 per 10 letters, p = 0.006), as well as presence of subretinal hyperreflective material (SHRM; OR 10.80, p < 0.001), intraretinal fluid (IRF; OR 2.60, p = 0.025), and type 2 macular neovascularisation (MNV; OR 2.98, p = 0.033) were each independently associated with fibrosis, while drusen presence was protective (OR 0.25, p = 0.002). Fibrosis occurred in 4.6% of eyes without SHRM and 43.0% with SHRM. In exploratory unadjusted analyses, odds of fibrosis were higher with SHRM height 1–99 µm (OR 6.2, 95% CI 1.8–21.7) and ≥100 µm (OR 23.7, 95% CI 7.9–71.3) than with no SHRM, and higher with ≥100 µm than 1–99 µm (OR 3.8, 95% CI 1.6–9.1; p = 0.003). Conclusions: Subretinal hyperreflective material was the strongest baseline biomarker for developing subretinal fibrosis following anti-VEGF therapy in this historical cohort, with exploratory analyses suggesting higher risk at SHRM ≥ 100 µm. In combination with other biomarkers, these features may support future risk stratification in treatment-naïve neovascular age-related macular degeneration.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →